

REFERENCES

- Baumgarten, M. and Gehr, T. 2011. Chronic kidney disease: detection and evaluation. *American family physician* 84(10): 1138.
- Beall, C.J., Mahajan, S. and Kolattukudy, P.E. 1996. Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity. *Biochemical Journal* 313(2): 633-640.
- Bonventre, J.V. and Yang, L. 2011. Cellular pathophysiology of ischemic acute kidney injury. *The Journal of clinical investigation* 121(11): 4210.
- Cirillo, P., Sato, W., Reungjui, S., Heinig, M., Gersch, M., Sautin, Y., Nakagawa, T. and Johnson, R.J. 2006. Uric acid, the metabolic syndrome, and renal disease. *Journal of the American Society of Nephrology* 17(12 suppl 3): S165-S168.
- Cochran, B.H., Reffel, A.C. and Stiles, C.D. 1983. Molecular cloning of gene sequences regulated by platelet-derived growth factor. *Cell* 33(3): 939-947.
- Cojocar, E., Trandafirescu, M., Leon, M., Cotutiu, C. and Foia, L. 2012. Immunohistochemical expression of anti-CD68 antibody in atherosclerotic plaque. *Rom J Morphol Embryol* 53(1): 61-66.
- Coresh, J., Byrd-Holt, D., Astor, B.C., Briggs, J.P., Eggers, P.W., Lacher, D.A. and Hostetter, T.H. 2005. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. *Journal of the American Society of Nephrology* 16(1): 180-188.
- Dalbeth, N. And Merimman, T. 2009. Crystal ball gazing: new therapeutic targets for hyperuricemia and gout. *Rheumatology* 48(3): pp.222-226
- Deshmane, S.L., Kremlev, S., Amini, S. and Sawaya, B.E. 2009. Monocyte chemoattractant protein-1 (MCP-1):

an overview. *Journal of interferon & cytokine research* 29(6): 313-326.

Di Gregorio, G.B., Yao-Borengasser, A., Rasouli, N., Varma, V., Lu, T., Miles, L.M., Ranganathan, G., Peterson, C.A., McGehee, R.E. and Kern, P.A. 2005. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues association with cytokine expression, insulin resistance, and reduction by pioglitazone. *Diabetes* 54(8): 2305-2313.

Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S.H., Hosoyamada, M., Takeada, M., Sekine, T., Igarashi, T. and Matsuo, H. 2002. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. *Nature* 417(6887): 447-452.

Feig, D.I., Mazzali, M., Kang, D.H., Nakagawa, T., Price, K., Kannelis, J. And Johnson, R.J. 2006. Serum uric acid: a risk factor and a target for treatment?. *Journal of the American Society of Nephrology* 17(4 suppl 2): S69-S73.

Giordano, C., Karasik, O., King-Morris, K. And Asmar, A. 2015. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. *Disease Markers*.

Guijarro, C. and Egidio, J. 2001. Transcription factor- κ B (NF- κ B) and renal disease. *Kidney international* 59(2): 415-424.

Haynes, R.J. and Winearls, C.G. 2010. Chronic kidney disease. *Surgery (Oxford)* 28(11): 525-529.

Holness, C.L. and Simmons, D.L. 1993. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. *Blood* 81(6): 1607-1613.

Jercan, O.F.E.L.I.A., Penescu, M. and Malaescu, D.G. 2012. Immunoexpression of alpha-SMA and CD68 in native kidney biopsies. *Rom J Morphol Embryol* 53(4): 1037-1042.

Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A.Y.M. and Yang, C.W. 2013. Chronic kidney disease: global

dimension and perspectives. *The Lancet* 382(9888): 260-272.

Johnson, R.J., Kang, D.H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., Tuttle, K.R., Rodriguez-Iturbe, B., Herrera-Acosta, J. and Mazzali, M. 2003. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. *Hypertension* 41(6): 1183-1190.

Johnson, C.A., Levey, A.S., Coresh, J., Levin, A., Lau, J. and Eknoyan, G. 2004. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. *American family physician* 70(5).

Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K.I., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K and Kasuga, M. 2006. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *The Journal of clinical investigation* 116(6): 1494-1505.

Kang, D.H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R. and Johnson, R.J. 2002. A role for uric acid in the progression of renal disease. *Journal of the American Society of Nephrology* 13(12): 2888-2897.

Kono, H., Chen, C.J., Ontiveros, F., and Rock, K.L. 2010. Uric acid promotes an acute inflammatory response to sterile cell death in mice. *The Journal of clinical investigation* 120(6): 1939-1949.

Levey, A.S., Eckardt, K.U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D.D., Hostetter, T.H., Lameire, N. and Eknoyan, G. 2005. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney international* 67(6): 2089-2100.

Lloyd, C.M., Minto, A.W., Dorf, M.E., Proudfoot, A., Wells, T.N., Salant, D.J. and Gutierrez-Ramos, J.C. 1997. RANTES and monocyte chemoattractant

protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. *The Journal of experimental medicine* 185(7): 1371-1380.

Mazzali, M., Kanellis, K., Han, L., Feng, L., Xia, Y.Y., Chen, Q., Kang, D.H., Gordon, K.L., Watanabe, S., Nakagawa, T. and Lan, H.Y. 2002. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. *American Journal of Physiology-Renal Physiology* 282(6): F991-F997.

McMichael, A.J. 1987. Leucocyte typing III: white cell differentiation antigens. Oxford University Press, USA.

Mescher, A.L 2010, *Junqueira's Basic Histology. Twelfth Edition*, The McGraw-Hill Companies, United States of America, Inc.

Micklem, K., Rigney, E., Cordell, J., Simmons, D., Stross, P., Turley, H., Seed, B. and Mason, D. 1989. A human macrophage-associated antigen (CD68) detected by six different monoclonal antibodies. *British journal of haematology* 73(1): 6-11.

Nangaku, M. 2006. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *Journal of the American Society of Nephrology* 17(1): 17-25.

Netea, M.G., Kullber, B.J., Blok, W.L., Netea, R.T., and Van der Meer, J.W. 1997. The role of hyperuricemia in the increased cytokine production after lipopolysaccharise challenge in neutropenic mice. *Blood* 89(2): 577-582.

Obermayr, R.P., Temml, C., Gutjahr, G., Knechtelsdorfer, M., Oberbauer, R. and Klauser-Braun, R. 2008. Elevated uric acid increases the risk for kidney disease. *Journal of the American Society of Nephrology* 19(12): 2407-2413.

Ohno, I. 2011. Relationship between hyperuricemia and chronic kidney disease. *Nucleosides, Nucleotides and Nucleic Acids* 30(12): 1039-1044.

- Petrovichev, N.N., Chistyakova, O.V., Smirnov, A.V., Poltoranina, V.S. and Rudinskaya, T.D. 1997. Antimacrophage monoclonal antibody D11 in the diagnosis of tumors of hystiocytic origin. *Acta cytologica* 41(2): 357-363.
- Ren, S., Fan, X., Peng, L., Pan, L., Yu, C., Tong, J., Zhang, W. and Liu, P. 2013. Expression of NF- κ B, CD68 and CD105 in carotid atherosclerotic plaque. *Journal of thoracic disease* 5(6): 771-776.
- Rodríguez-Iturbe, B., Johnson, R.R. and Herrera-Acosta, J. 2005. Tubulointerstitial damage and progression of renal failure. *Kidney International* 68: S82-S86.
- Sah, O.S.P. and Qing, Y.X. 2015. Associations Between Hyperuricemia and Chronic Kidney Disease: A Review. *Nephro-urology monthly* 7(3)
- Segerer, S., Nelson, P.J. and SCHLÖNDORFF, D. 2000. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. *Journal of the American Society of Nephrology* 11(1): 152-176.
- Srikrishna, G. and Freeze, H.H. 2009. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. *Neoplasia* 11(7): 615-628.
- Tesch, G.H., Schwarting, A., Kinoshita, K., Lan, H.Y., Rollins, B.J. and Kelley, V.R. 1999. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. *The Journal of clinical investigation* 103(1): 73-80.
- Viedt, C., Vogel, J., Athanasiou, T., Shen, W., Orth, S.R., Kübler, W. and Kreuzer, J. 2002. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor- κ B and activator protein-1. *Arteriosclerosis, thrombosis, and vascular biology* 22(6): 914-920.

- Wagner, W., Roderburg, C., Wein, F., Diehimman, A., Frankhauser, M., Schubert, R., Eckstein, V. and Ho, A.D. 2007. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. *Stem Cells* 25(10): 2638-2647.
- Yang, Z., Xiaohua, W., Lei, J., Ruoyun, T., Mingxia, X., Weichun, H., Li, F., Ping, W. and Junwei, Y. 2010. Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. *American Journal of Physiology-Renal Physiology* 299(2): F336-F346.
- Zhang, Q.L. and Rothenbacher, D. 2008. Prevalence of chronic kidney disease in population-based studies: systematic review. *BMC public health* 8(1): 1.
- Zoccali, C., Maio, R., Mallamaci, F., Sesti, G. and Perticone, F. 2006. Uric acid and endothelial dysfunction in essential hypertension. *Journal of the American Society of Nephrology* 17(5): 1466-1471.
- Zhou, Y., Fang, L., Jiang, L., Wen, P., Cao, H., He, W., Dai, C. and Yang, J. 2012. Uric acid induces renal inflammation via activating tubular NF- κ B signaling pathway. *PloS one* 7(6): e39738.